Lineage Cell Therapeutics (LCTX) Current Assets (2010 - 2026)

Lineage Cell Therapeutics has reported Current Assets for 17 years, with the latest figure at $56.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 12.36% year-over-year to $56.2 million; the trailing twelve-month figure through Mar 2026 stood at $56.2 million (up 12.36% YoY), and the FY2025 full-year result was $59.2 million, up 16.0% from the prior year.
• Current Assets for Q1 2026 stood at $56.2 million, down from $59.2 million in the prior quarter.
• The five-year high for Current Assets was $81.9 million in Q1 2022, with the low at $34.4 million in Q3 2024.
• Historically, Current Assets has averaged $52.2 million across 5 years, with a median of $49.7 million in 2023.
• Annual changes were most pronounced in 2022 — Current Assets plunged 46.21% — and 2024, when it soared 32.66%.
• Lineage Cell Therapeutics' Current Assets stood at $60.0 million in 2022, then tumbled by 35.93% to $38.4 million in 2023, then soared by 32.66% to $51.0 million in 2024, then increased by 16.0% to $59.2 million in 2025, then decreased by 5.06% to $56.2 million in 2026.
• The last three Current Assets figures came in at $56.2 million (Q1 2026), $59.2 million (Q4 2025), and $42.3 million (Q3 2025), per Business Quant data.